Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Anticoagulant activity of edoxaban in patients with cirrhosis

Sarah Bos, Tim Schreuder, Hans Blokzijl, Jelle Adelmeijer, Ton Lisman, Pieter W. Kamphuisen

Blood (2020) 136 (13): 1561–1564.

https://doi.org/10.1182/blood.2020005319

Published: 2020

Journal Articles

Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey

Alexander B Pine, MD PhD, Alfred I Lee, MD PhD

Blood (2019) 134 (Supplement_1): 2097.

https://doi.org/10.1182/blood-2019-130200

Published: 2019

Journal Articles

Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119)

Sandra Marten, MD, Luise Tittl, Christiane Naue, MD, Jan Beyer-Westendorf, MD

Blood (2019) 134 (Supplement_1): 3667.

https://doi.org/10.1182/blood-2019-126535

Published: 2019

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

Renata Almeida Sa, MSc, BSc, Fatimah Al-Ani, MD MRCP, Alejandro Lazo-Langner, MD MSc, Martha L Louzada, MDMSc

Blood (2019) 134 (Supplement_1): 3675.

https://doi.org/10.1182/blood-2019-121765

Published: 2019

Journal Articles

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Pável E Olivera, MD, César A Velasquez, MD, Desirée Campoy, MD, Gonzalo Artaza, MD, Tania Canals, MD, Katia Flores, MD, Silvia Ruiz, MD, Alessandra Comai, MD, Erik A Johansson, MD, Gabriela S Ene, MD PhD, Gabriela Bastidas, MD, Maricel Subira, MD PhD, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2019) 134 (Supplement_1): 3661.

https://doi.org/10.1182/blood-2019-128300

Published: 2019

Journal Articles

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Debra Hoppensteadt, PhD, Emily Bontekoe, Fakiha Siddiqui, Ambar Farooqui, Omer Iqbal, MD, Walter Jeske, PhD, Jeanine Walenga, PhD, Alfonso J Tafur, MD MS, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 3374.

https://doi.org/10.1182/blood-2019-131221

Published: 2019

Journal Articles

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Desirée Campoy, MD, Gonzalo Artaza, MD, César A Velasquez, MD, Tania Canals, MD, Erik A Johansson, MD, Katia Flores, MD, Gabriela Bastidas, MD, Silvia Ruiz, MD, Gabriela S Ene, MD PhD, Alessandra Comai, MD, Maricel Subira, MD PhD, Ramón Salinas, MD PhD, Jorge Sierra, MD, Pável E Olivera, MD

Blood (2019) 134 (Supplement_1): 1162.

https://doi.org/10.1182/blood-2019-125150

Published: 2019

Journal Articles

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Michiel Coppens, MD, Lizhen Xu, PhD, Roisin Bavalia, MD, Saskia Middeldorp, MD PhD, Peter Verhamme, MD PhD, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Mark Crowther, MD, Genmin Lu, Patrick Yue, MD, Pamela B. Conley, PhD, Stuart J. Connolly, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 711.

https://doi.org/10.1182/blood-2019-124596

Published: 2019

Journal Articles

Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis

Shuchi Gulati, MD, Zizi Elsisi, Smruti Deoghare, Mark Eckman

Blood (2019) 134 (Supplement_1): 328.

https://doi.org/10.1182/blood-2019-124756

Published: 2019

Journal Articles

Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails

Sariya Wongsaengsak, MD, Somedeb Ball, MD, Nuvneet Khandelwal, MD, Alay Tikue, MD, Arunee Motes, Nusrat Jahan, MD, Kyaw Zin Thein, MDMBBS, Lukman Tijani, MD

Blood (2019) 134 (Supplement_1): 4962.

https://doi.org/10.1182/blood-2019-125473

Published: 2019

Journal Articles

Clinical Outcomes of Multiple Myeloma Patients Treated with Direct Oral Anticoagulants for Immunomodulatory Drug Associated Venous Thromboembolism

Zachary Crowther, Jamie Doyle, Stanford Taylor, Nadia Ali, MD

Blood (2019) 134 (Supplement_1): 4964.

https://doi.org/10.1182/blood-2019-131396

Published: 2019

Journal Articles

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Andrew Doyle, MBBS, BSc, FRPATH, Karen Breen, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia, Beverley J. Hunt, Gavin Ling, MBBS, BSc, FRCPath, Claire N Harrison, Professor, Natalia Curto Garcia, MD MBBS

Blood (2019) 134 (Supplement_1): 4183.

https://doi.org/10.1182/blood-2019-128170

Published: 2019

Journal Articles

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Siddharth Mehrotra, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Alfonso J Tafur, MD MS, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1155.

https://doi.org/10.1182/blood-2019-131907

Published: 2019

Journal Articles

Characterizing the Use of Direct Oral Anticoagulants in Children Using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset)

Jennifer G. Davila, MD, Dunlei Cheng, PhD, Leslie J. Raffini, MD, Courtney D. Thornburg, MD, Fernando F. Corrales-Medina, MD

Blood (2019) 134 (Supplement_1): 1156.

https://doi.org/10.1182/blood-2019-128324

Published: 2019

Journal Articles

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

Jordan K Schaefer, MD, Yun Li, PhD, Xiaowen Kong, MA, Tina Alexandris-Souphis, RN, Mona A Ali, PharmD, Brian Haymart, RN, MS, Scott Kaatz, DO, MSc, Eva Kline-Rogers, RN, MS, Jay H Kozlowski, MD, Gregory D Krol, Sahana R Shankar, Suman L Sood, MD, James B Froehlich, MD MPH, Geoffrey D Barnes, MD MSc

Blood (2019) 134 (Supplement_1): 787.

https://doi.org/10.1182/blood-2019-122526

Published: 2019

Journal Articles

A Direct Oral Anticoagulant Edoxaban Enhanced Fibrinolysis Via Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor Activation and Enhancement of Plasmin Generation in Human Plasma

Yoshiyuki Morishima, PhD, Yuko Honda, Taketoshi Furugohri, PhD

Blood (2018) 132 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2018-99-109724

Published: 2018

Journal Articles

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Fakiha Siddiqui, Siddharth Mehrotra, Vishnu Venkitasubramony, Rithik Raina, Lorenzo Storino Ramacciotti, Jack Bontekoe, BS, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Jawed Fareed, PhD

Blood (2018) 132 (Supplement 1): 2520.

https://doi.org/10.1182/blood-2018-99-116993

Published: 2018

Journal Articles

Bleeding Risk of Low-Molecular Weight Heparin Vs Direct Oral Anticoagulant in Patients with Intracranial Tumors

R Sumner Abraham, IV, MD, Trish A Millard, MD, Surabhi Palkimas, PharmD, Nolan A Wages, PhD, Hillary S. Maitland, MD MS

Blood (2018) 132 (Supplement 1): 2524.

https://doi.org/10.1182/blood-2018-99-113949

Published: 2018

Journal Articles

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience

Kamila I. Cisak, MD, Dennis Asante, MS, Diane E. Grill, MS, Aneel A. Ashrani, MD, M.S.

Blood (2018) 132 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2018-99-117607

Published: 2018

NARROW

Anticoagulant activity of edoxaban in patients with cirrhosis

Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey

Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119)

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis

Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails

Clinical Outcomes of Multiple Myeloma Patients Treated with Direct Oral Anticoagulants for Immunomodulatory Drug Associated Venous Thromboembolism

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Characterizing the Use of Direct Oral Anticoagulants in Children Using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset)

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

A Direct Oral Anticoagulant Edoxaban Enhanced Fibrinolysis Via Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor Activation and Enhancement of Plasmin Generation in Human Plasma

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Bleeding Risk of Low-Molecular Weight Heparin Vs Direct Oral Anticoagulant in Patients with Intracranial Tumors

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only